We are live on ! Find out more
CNSP icon

CNS Pharmaceuticals
CNSP

1 hedge funds and large institutions have $232K invested in CNS Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more ownership

Funds ownership: 0% → 0% (+0%)

32% less capital invested

Capital invested by funds: $343K → $232K (-$111K)

Holders
1
Holders Change
+1
Holders Change %
–
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$214K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$6K
2
UCFA
United Capital Financial Advisors
Texas
-$5K
3
SG
StoneX Group
New York
-$4.46K
4
Citigroup
Citigroup
New York
-$4K
5
Millennium Management
Millennium Management
New York
-$3K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$81K +$214K +1 New
Bank of New York Mellon
2
Bank of New York Mellon
New York
$36K – – –
Geode Capital Management
3
Geode Capital Management
Massachusetts
$23K – – –
VF
4
Virtu Financial
New York
$23K – – –
TSS
5
Two Sigma Securities
New York
$16K – – –
Renaissance Technologies
6
Renaissance Technologies
New York
$10K – – –
FWA
7
FSM Wealth Advisors
Ohio
$7K – – –
Northern Trust
8
Northern Trust
Illinois
$6K – – –
TRCT
9
Tower Research Capital (TRC)
New York
$6K – – –
Cambridge Investment Research Advisors
10
Cambridge Investment Research Advisors
Iowa
$5K – – –
State Street
11
State Street
Massachusetts
$4K – – –
Commonwealth Equity Services
12
Commonwealth Equity Services
Massachusetts
$3K – – –
Goldman Sachs
13
Goldman Sachs
New York
$3K – – –
HighTower Advisors
14
HighTower Advisors
Illinois
$3K – – –
ACI
15
Alpha Cubed Investments
California
$2K – – –
PCIA
16
Prime Capital Investment Advisors
Kansas
$2K – – –
Wells Fargo
17
Wells Fargo
California
$2K – – –
Citadel Advisors
18
Citadel Advisors
Florida
– -$6K – –
Citigroup
19
Citigroup
New York
– -$4K – –
Millennium Management
20
Millennium Management
New York
– -$3K – –
SG
21
StoneX Group
New York
– -$4.46K – –
UCFA
22
United Capital Financial Advisors
Texas
– -$5K – –

CNSP Hedge Fund Activity: Q3 2022 in Review

1 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in CNS Pharmaceuticals (CNSP) for Q3 2022, worth a combined $232K — down 32% from $343K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new CNSP positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Vanguard Group, opening a new position worth an estimated $214K. The largest seller was Citadel Advisors, cutting an estimated $6K.

  • 1 institutional investor held CNS Pharmaceuticals (CNSP) as of Q3 2022, up from 0 in Q2 2022.
  • Funds reported $232K of CNS Pharmaceuticals stock for Q3 2022, down 32% quarter-over-quarter.
  • 1 fund opened new CNS Pharmaceuticals positions in Q3 2022 and 0 closed out, a net change of +1 holder.
  • The largest CNS Pharmaceuticals buyer in Q3 2022 was Vanguard Group, an estimated $214K added.
  • The largest CNS Pharmaceuticals seller in Q3 2022 was Citadel Advisors, an estimated $6K sold.

Based on aggregated 13F filings for Q3 2022.